Medexus Schedules Third Quarter Fiscal 2022 Conference Call
January 31, 2022 08:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at...
Medexus to Present at the H.C. Wainwright BioConnect 2022 Conference
January 07, 2022 09:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive...
Medexus to Participate in Two Upcoming Virtual Investor Conferences
December 02, 2021 16:15 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive...
Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan
December 02, 2021 08:08 ET
|
Medexus Pharmaceuticals Inc
NDA resubmission expected in second calendar quarter 2022 (previously anticipated timeline)Final FDA decision expected 2 to 6 months after NDA resubmissionNo additional Phase III study is required ...
Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021
November 10, 2021 17:00 ET
|
Medexus Pharmaceuticals Inc
Achieved $17.9 million revenue driven by continued strength of Rupall™ Positioned for revenue growth along with expected recovery of IXINITY® sales Commercially launched Trecondyv® (treosulfan) in...
Medexus to Present at the Q4 Investor Summit on November 17th
November 10, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that management will present at the Q4...
Medexus Pharmaceuticals Announces Appointment of Internal Counsel
November 08, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed Ian C Wildgoose Brown...
Medexus Schedules Second Quarter Fiscal 2022 Conference Call
November 04, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at...
Medexus Pharmaceuticals Announces Type A Meeting with FDA Granted for Treosulfan
November 01, 2021 09:27 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) today announced that the U.S. Food...
Medexus to Present at the Benzinga Global Small Cap Conference on October 28, 2021
October 26, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief...